This trial is planned to enroll 800 patients with any histology metastatic NSCLC with PD-L1 ≥1% (stratified by whether levels are ≥50% or less) and will be randomized to one of three arms. The gene discussed is CD274; the disease is non-small cell lung carcinoma.